Company Filing History:

13 out of 677

Eisai Company, Limited

patents

2 out of 527

Eisai R&d Management Co., Ltd.

patents

Years Active: 1990-2015

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9018260 - Indanesulfamide derivatives (2015-04-28),

2. 7378425 - (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds (2008-05-27),

3. 7091218 - 4-substituted piperidine compound (2006-08-15),

4. 6906083 - 4-substituted piperidine compound (2005-06-14),

5. 6706741 - Acetylcholinesterase inhibitors containing 1-benzyl-pyridinium salts (2004-03-16),

6. 6677330 - Fluorides of 4-substituted piperidine derivatives (2004-01-13),

7. 6277866 - 1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine (2001-08-21),

8. 5919778 - Cyclic amide derivatives (1999-07-06),

9. 5654308 - Bicyclic amide derivatives, compositions and methods of treatment (1997-08-05),

10. 5620976 - Benzoxazine derivatives (1997-04-15),

11. 5521182 - 1,2,3,4 tetrahydropteridinone cyclic amide derivatives (1996-05-28),

12. 5504088 - 2H-3,4-tetrahydroquinazoline-2-one and (1996-04-02),

13. 5292735 - Cyclic amide derivatives (1994-03-08),

14. 5100901 - Cyclic amine compounds and pharmaceutical use (1992-03-31),

15. 4895841 - Cyclic amine compounds with activity against acetylcholinesterase (1990-01-23),

Title: Takashi Kosasa: Innovator in Pharmaceutical Chemistry

Introduction

Takashi Kosasa is a prominent inventor based in Ibaraki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 15 patents. His work focuses on developing novel compounds that have the potential to treat various medical conditions, particularly epilepsy.

Latest Patents

Among his latest patents are the indanesulfamide derivatives, which include compounds such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide and N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide. These compounds have shown promise in improving the Seizure Severity Index in mice kindling models, indicating their potential as drugs for treating epilepsy. Additionally, he has developed (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds, which serve as excellent sigma receptor binding agents and acetylcholinesterase inhibitors.

Career Highlights

Throughout his career, Takashi Kosasa has worked with notable companies, including Eisai Company, Limited and Eisai R&D Management Co., Ltd. His innovative research has led to advancements in drug development, particularly in the area of neurological disorders.

Collaborations

He has collaborated with esteemed colleagues such as Yoshiharu Yamanishi and Hachiro Sugimoto, contributing to a rich exchange of ideas and expertise in the pharmaceutical field.

Conclusion

Takashi Kosasa's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a key figure in the development of new treatments for epilepsy and other medical conditions. His work continues to inspire advancements in the field.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent (CIPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.